Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2003 Feb;40(2):109–114. doi: 10.1136/jmg.40.2.109

Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas

L Kluwe 1, V Mautner 1, B Heinrich 1, R Dezube 1, L Jacoby 1, R Friedrich 1, M MacCollin 1
PMCID: PMC1735360  PMID: 12566519

Abstract

Neurofibromatosis 2 (NF2) is a severe autosomal dominant disorder that predisposes to multiple tumours of the nervous system. About half of all patients are founders with clinically unaffected parents. The purpose of the present study was to examine the extent to which mosaicism is present in NF2 founders. A total of 233 NF2 founders with bilateral vestibular schwannomas (BVS) were screened by exon scanning. NF2 mutations were detected in the blood samples of 122 patients (52%). In 10 of the 122 cases, the ratio of mutant to normal alleles was obviously less than 1, suggesting mosaicism. Tumour specimens were available from 35 of the 111 subjects in whom no mutation could be detected in blood specimens. Mutational analysis by exon scanning detected typical NF2 mutations in 21 of the 35 tumours. In nine subjects, the alterations found in tumours could be confirmed to be the constitutional mutation based on finding of identical mutations in pathologically and/or anatomically distinct second tumours. In six other subjects with only a single tumour available, allelic loss of the NF2 gene was found in addition to the mutation in each tumour, suggesting that either the mutation or the deletion of the NF2 gene is probably the constitutional genetic alteration. Our results suggest that failure to find constitutional mutations in blood specimen from these 15 patients was not because of the limitation of the applied screening technique, but the lack of the mutations in their leucocytes, best explained by mosaicism. Extrapolating the rate (15/35 = 43%) of mosaicism in these 35 cases to the 111 NF2 founders with no constitutional NF2 mutations found in their blood, we inferred 48 mosaic subjects (111 x 0.429). Adding the 10 mosaic cases detected directly in blood specimens, we estimate the rate of mosaicism to be 24.8% (58/233) in our cohort of 233 NF2 founders with bilateral vestibular schwannomas.

Full Text

The Full Text of this article is available as a PDF (184.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bijlsma E. K., Wallace A. J., Evans D. G. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet. 1997 Nov;34(11):934–936. doi: 10.1136/jmg.34.11.934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bourn D., Carter S. A., Evans D. G., Goodship J., Coakham H., Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet. 1994 Jul;55(1):69–73. [PMC free article] [PubMed] [Google Scholar]
  3. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  4. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans D. G., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998 Jun;35(6):450–455. doi: 10.1136/jmg.35.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans D. G., Wallace A. J., Wu C. L., Trueman L., Ramsden R. T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. doi: 10.1086/512074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gutmann D. H., Aylsworth A., Carey J. C., Korf B., Marks J., Pyeritz R. E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997 Jul 2;278(1):51–57. [PubMed] [Google Scholar]
  8. Jacoby L. B., Jones D., Davis K., Kronn D., Short M. P., Gusella J., MacCollin M. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997 Dec;61(6):1293–1302. doi: 10.1086/301633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jacoby L. B., MacCollin M., Barone R., Ramesh V., Gusella J. F. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer. 1996 Sep;17(1):45–55. doi: 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  10. Jacoby L. B., MacCollin M., Louis D. N., Mohney T., Rubio M. P., Pulaski K., Trofatter J. A., Kley N., Seizinger B., Ramesh V. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994 Mar;3(3):413–419. doi: 10.1093/hmg/3.3.413. [DOI] [PubMed] [Google Scholar]
  11. Jacoby L. B., MacCollin M., Parry D. M., Kluwe L., Lynch J., Jones D., Gusella J. F. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics. 1999 Apr;2(2):101–108. doi: 10.1007/s100480050060. [DOI] [PubMed] [Google Scholar]
  12. Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Fünsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. doi: 10.1007/s004390050255. [DOI] [PubMed] [Google Scholar]
  13. Kluwe L., MacCollin M., Tatagiba M., Thomas S., Hazim W., Haase W., Mautner V. F. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998 May 18;77(3):228–233. [PubMed] [Google Scholar]
  14. Kluwe L., Mautner V. F. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998 Dec;7(13):2051–2055. doi: 10.1093/hmg/7.13.2051. [DOI] [PubMed] [Google Scholar]
  15. Kluwe L., Mautner V., Parry D. M., Jacoby L. B., Baser M., Gusella J., Davis K., Stavrou D., MacCollin M. The parental origin of new mutations in neurofibromatosis 2. Neurogenetics. 2000 Sep;3(1):17–24. doi: 10.1007/s100480000088. [DOI] [PubMed] [Google Scholar]
  16. Kluwe Lan, Friedrich Reinhard E., Tatagiba Marcos, Mautner Victor F. Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med. 2002 Jan-Feb;4(1):27–30. doi: 10.1097/00125817-200201000-00005. [DOI] [PubMed] [Google Scholar]
  17. MacCollin M., Braverman N., Viskochil D., Ruttledge M., Davis K., Ojemann R., Gusella J., Parry D. M. A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol. 1996 Sep;40(3):440–445. doi: 10.1002/ana.410400313. [DOI] [PubMed] [Google Scholar]
  18. MacCollin M., Ramesh V., Jacoby L. B., Louis D. N., Rubio M. P., Pulaski K., Trofatter J. A., Short M. P., Bove C., Eldridge R. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994 Aug;55(2):314–320. [PMC free article] [PubMed] [Google Scholar]
  19. Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. doi: 10.1097/00006123-199605000-00004. [DOI] [PubMed] [Google Scholar]
  20. Murgia A., Martella M., Vinanzi C., Polli R., Perilongo G., Opocher G. Somatic mosaicism in von Hippel-Lindau Disease. Hum Mutat. 2000 Jan;15(1):114–114. doi: 10.1002/(SICI)1098-1004(200001)15:1<114::AID-HUMU20>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  21. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  22. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  23. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  24. Ruggieri M., Huson S. M. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology. 2001 Jun 12;56(11):1433–1443. doi: 10.1212/wnl.56.11.1433. [DOI] [PubMed] [Google Scholar]
  25. Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed] [Google Scholar]
  26. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  27. Zucman-Rossi J., Legoix P., Der Sarkissian H., Cheret G., Sor F., Bernardi A., Cazes L., Giraud S., Ollagnon E., Lenoir G. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet. 1998 Dec;7(13):2095–2101. doi: 10.1093/hmg/7.13.2095. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES